Model Medicines is a biotechnology company engineering first-in-class small molecules that target the biological linchpins underlying disease. The company’s research spans virology, oncology, and inflammation, with programs designed around conserved biological choke points that drive multiple pathologies. Model Medicines had discovered a direct-acting, non-nucleoside, broad-spectrum antiviral and a BRD4 inhibitor with no measurable activity against BRD2/3. Its work demonstrates how large-scale computation can uncover entirely new classes of drugs once thought unreachable. Model Medicines is advancing a new generation of therapeutics that redefine what is possible in modern drug discovery. Learn more at www.modelmedicines.com.